Meine wissenschaftlichen Publikationen findest Du hier: https://www.ncbi.nlm.nih.gov/pubmed/?term=sachse-seeboth+c
1. Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. Matthaei J, Tzvetkov MV, Gal V, Sachse-Seeboth C, Sehrt D, Hjelmborg JB, Hofmann U, Schwab M, Kerb R, Brockmöller J. Genome Med. 2016 Nov 8;8(1):119.
2. Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2. Matthaei J, Tzvetkov MV, Strube J, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Möller S, Halekoh U, Hofmann U, Schwab M, Kerb R, Brockmöller J. Clin Pharmacol Ther. 2016 Dec;100(6):606-616. doi: 10.1002/cpt.444. Epub 2016 Sep 23.
3. Heritability of metoprolol and torsemide pharmacokinetics. Matthaei J, Brockmöller J, Tzvetkov MV, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Möller S, Halekoh U, Hofmann U, Schwab M, Kerb R. Clin Pharmacol Ther. 2015 Dec;98(6):611-21. doi: 10.1002/cpt.258. Epub 2015 Oct 19.
4. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Sachse-Seeboth C, Pfeil J, Sehrt D, Meineke I, Tzvetkov M, Bruns E, Poser W, Vormfelde SV, Brockmöller J. Clin Pharmacol Ther. 2009 Mar;85(3):273-6. doi: 10.1038/clpt.2008.213. Epub 2008 Nov 12.
5. Role of variant Creutzfeldt-Jakob disease for safety of treatment with blood components: screening of lymphatic tissue is a potential tool for risk assessment. Sachse C, Groschup MH, Warzok R, Greinacher A. Eur J Haematol. 2003 Jan;70(1):11-6.